Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Propofol Pharmacokinetics in Patients with Obstructive Jaundice

Author(s): J. C. Song, Y. M. Sun, M. Z. Zhang, L. Q. Yang, J. G. Song, Z. M. Wang and W. F. Yu

Volume 6, Issue 3, 2009

Page: [317 - 320] Pages: 4

DOI: 10.2174/156720109788680903

Price: $65

Abstract

The effect of obstructive jaundice on the distribution and elimination of propofol was studied in 15 patients with obstructive jaundice (total serum bilirubin, TBL 17.1μmol.l ) and in 15 control patients (TBL < 17.1μmol.l ). Following an i.v. bolus dose of propofol (2-2.5 mg.kg ) multiple arterial samples were obtained at timed intervals for 4 h and blood concentrations of propofol were measured by high pressure liquid chromatography. Compartmental analysis of propofol concentrations revealed a three-compartment model with elimination from a central compartment in all patients. Pharmacokinelic parameters: volumes of distribution at steady state (V ), volumes of distribution at equilibrium (Vr), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg , 32.99(21.42 ) litre.kg-1, 0.241(0.131) litre.kg-1, and 28.8(8.2) ml.min-1.kg respectively) compared with contro1 group (11.9 (5.4) litre.kg , 28.30(13.70) litre.kg-1, 0.297(0.112) litre.kg-1, and 33.9(7.6) ml.min-1.kg respectively) (P > 0.05). Half-times of the three phases ( T1/2 ,T1/2 ,T1/2 ) were also similar between both groups.We conclude that in patients with obstructive jaundice the pharmacokinetics of propofol are similar to those of patients without obstructive jaundice.

Keywords: Anaesthetics i.v., propofol, pharmacokinetics, liver-bile

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy